Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AbbVie Inc. (ABBV) Closing on a $53 Billion Takeover of Shire PLC (ADR) (SHPG)

Questions are being asked as to whether Shire PLC (ADR) (NASDAQ:SHPG) shareholders will finally agree to the latest offer of £53.20 by AbbVie Inc. (NYSE:ABBV) as the stock continues to remain flat in the market. Delmore Asset Management Founder, Howard Goldring, has told CNBC that Shire shareholders might discount the offer considering it is not an all cash transaction, while also stating that the share price is almost close, but not yet there for approval.

Shire PLC (ADR)

Goldring has also said that most of the shareholders at Shire PLC (ADR) (NASDAQ:SHPG) must be happy at the moment considering the company’s value a few months back was about £30-£35.

“The price is getting close but not absolutely up to that level. However, most of the shareholders in Shire must be quite happy this morning, 6-7 weeks ago the price was around 35 pounds. This offer is an extremely good offer for them,” said Mr. Goldring.

Shire PLC (ADR) (NASDAQ:SHPG) remains a unique play for AbbVie Inc. (NYSE:ABBV) considering it has a pipeline of drugs that are well diversified. Shire according to Mr. Howard is quite clever at finding other companies with interesting research programs and interesting compounds in quite protected niche markets.

If successful, it will be a good deal for AbbVie Inc. (NYSE:ABBV) as it will broaden its portfolio while also offering tax reduction prospects in terms of operating as an Inversion in the U.K..

“They have got a very good pipeline; it is quite well diversified, and they are very clever at finding other companies with interesting research programs and interesting compounds,” said Mr. Goldring.

It is still not clear whether investors will sell theirs stakes in Shire considering the stock has only surged in the market after talks of a possible acquisition erupted.  The risks that come acquisitions as well as the effects of an inversion could be quite unbearable for some shareholders who might take up the opportunity and sell their interests in Shire PLC (ADR) (NASDAQ:SHPG).

There is also a risk of Shire PLC (ADR) (NASDAQ:SHPG)’s stock retracting to a flat after completion of the acquisition by AbbVie Inc. (NYSE:ABBV). Taking into consideration all this concerns Mr. Howard admitted if it were his investments he would consider ‘lightning’ the load.


Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!